Results 221 to 230 of about 3,679,356 (272)

Leveraging Hypomethylating Agents for Better MDS Therapy

Current Hematologic Malignancy Reports, 2018
Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy.
Terrence J, Bradley, Justin M, Watts, Ronan T, Swords   +2 more
openaire   +2 more sources

Hypomethylating Agents as a Therapy for AML

Current Hematologic Malignancy Reports, 2017
Acute myeloid leukemia (AML) is predominantly a disease of older adults associated with poor long-term outcomes with available therapies. Used as single agents, hypomethylating agents (HMAs) induce only 15 to 25% complete remissions, but current data suggest that median OS observed after HMAs is comparable to that observed after more intensive ...
Claude, Gardin, Hervé, Dombret
openaire   +2 more sources

Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents

Virchows Archiv
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While induction chemotherapy leads to remission in most patients, a significant number will experience relapse.
Mario L. Marques-Piubelli, Bijender Kumar, R. Başar, S. Panowski, Surabhi Srinivasan, Kevin Norwood, Sacha Prashad, Victoria Szenes, A. Balakumaran, Akanksha Arandhya, Wei Lu, Khaja B Khan, Daniela Duenas, S. McAllen, Javier A Gomez, Jared K. Burks, Sunil Acharyal, G. Borthakur, Wei-Lien Wang, W. Wang, Sa A. Wang, Luisa M. Solis, David Marin, K. Rezvani, May Daher, Francisco Vega   +25 more
semanticscholar   +1 more source

The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs

Cancer Journal, 2022
Azacitidine and decitabine are cytosine analogs that function as DNA methyltransferase inhibitors. These agents, commonly referred to as “hypomethylating agents,” are widely used for the treatment of myelodysplastic syndrome and acute myeloid leukemia ...
N. Short, H. Dombret, L. Adès, H. Kantarjian   +3 more
semanticscholar   +1 more source

Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways

Current Cancer Drug Targets, 2010
DNA methylation and histone acetylation are two most studied epigenetic markers. Aberrant methylation of gene promoter regions and histone tail lysine residue modification through acetylation and methylation play a key role in malignant disorders. Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy ...
S, Cang, Q, Lu, Y, Ma, D, Liu
openaire   +2 more sources

Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents

Current Opinion in Hematology, 2010
Several novel therapeutic approaches exist for treatment of patients with myelodysplastic syndrome, with goals to improve quality of life and prolong survival. This review highlights new therapies from the last 18 months.Immunosuppressants, erythropoiesis-stimulating agents in combination with granulocyte colony-stimulating factor or all-trans-retinoic-
Arturo, Loaiza-Bonilla, Steven D, Gore, Hetty E, Carraway   +2 more
openaire   +2 more sources

Treatment with Hypomethylating Agents (HMA)

2018
In 1993 Silverman and coworkers [1] reported on a phase 2 trial on 43 patients with higher-risk MDS (medullary blast count >10%) using 75 mg/m2 5-Azacytidine (5-Aza) for 7 days every 28 days for 6 cycles. Forty-nine percent of the patients responded, with 12% CR (CR and PR 37%, and 5% improved hematologically without achieving CR or PR), and 51% were ...
Ulrich Germing, Pierre Fenaux
openaire   +1 more source

Future Directions for the Use of Hypomethylating Agents

Seminars in Hematology, 2005
Epigenetics refers to heritable changes in DNA and chromatin that impact gene expression without a change in DNA sequence. Two major steps involved in epigenetic regulation of gene expression include methylation of the promoter region of the gene and deacetylation of specific lysine residues on promoter-associated histones leading to changes in ...
Guillermo, Garcia-Manero, Steven D, Gore
openaire   +2 more sources

Real‐world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts

American journal of hematology/oncology, 2022
Luspatercept vs imetelstat. Am J Hematol. 2021;96:761-763. 14. Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor Imetelstat for Myelofibrosis. N Engl J Med. 2015;373: 908-919. 15. Patnaik MM, Santini V. Targeting ineffective
N. Gangat, Kristen B. McCullough, I. Johnson, A. Al-Kali, K. Begna, M. Patnaik, M. Litzow, W. Hogan, M. Shah, H. Alkhateeb, A. Mangaonkar, J. Foran, T. Badar, J. Palmer, L. Sproat, Cecilia Y Arana Yi, A. Pardanani, A. Tefferi   +17 more
semanticscholar   +1 more source

Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis

Leukemia and Lymphoma, 2021
To describe real-world treatment patterns and outcomes among adult patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA), patients were identified in the SEER-Medicare database (01/2006–12/2016); 3,046 patients with MDS ...
E. Stein, G. Bonifacio, D. Latremouille-Viau, Sherry Shi, A. Guerin, E. Wu, I. Sadek, Xiting Cao   +7 more
semanticscholar   +1 more source